London, June 6, 2026, 21:02 (BST)
3i Group stayed on the back foot, closing out the week with losses despite a late session push. Questions about slowing sales at Action, 3i’s biggest holding, hung over the shares. Investors remain unsure if the weaker numbers are just a blip or a sign of deeper trouble.
London trading paused for the weekend. MarketScreener put 3i at 2,209 pence, adding 0.87% on Friday. The stock lost 2.90% over five days and is off 32.30% since Jan. 1.
3i’s shares have taken a big hit this year and the company isn’t set to release any new updates next week. With no new data, traders are left watching the buyback, listed private asset flows and signals from European consumers for direction. There’s not a lot of cushion here for 3i.
3i shares dropped 4.22% to 21.79 pounds on Monday as the FTSE 100 lost 0.68%. But by Thursday, 3i was up 2.77% at 21.90 pounds, ahead of the index’s 0.27% gain, MarketWatch data showed. The week stayed uneven.
3i announced a new deal for its portfolio. On June 3, the firm said it invested in Laboratoire Nutergia, a French natural supplements brand set up in 1989 and mostly sold in pharmacies. Pierre-Axel Botuha, partner and France private equity co-head at 3i, called Nutergia “a top-tier nutrition business” and said the company matches 3i’s approach of backing distinctive consumer health names. 3i
Nutergia isn’t what’s driving the stock right now. It’s about the action.
3i’s annual report on May 14 showed a 22% total return for the year ending March 31, with net asset value at 3,030 pence per share. The firm put up a share buyback for as much as 750 million pounds. Action posted a gross investment return of 4.51 billion pounds, though like-for-like sales growth dropped to 2.4% for the year to May 10, down from 6.8% last year. Chief Executive Simon Borrows called the “market environment” still “complex.” 3i
3i shares lost 15% on May 14 after Action’s sales growth cooled, according to the Financial Times. The paper pointed out that Action makes up nearly 75% of 3i’s investment portfolio. The market hasn’t forgotten that warning.
Analyst views are still split, but asset value estimates sit above the current market price. The company’s own consensus, which includes 12 analysts’ estimates from March 12 to May 20, puts the median NAV figure at 3,486 pence for March 31, 2027. 3i said these are analyst projections and do not represent its guidance.
The sector backdrop isn’t clear. Reuters reported this week that Partners Group has limited withdrawals from an $8.6 billion private equity fund, pressuring its shares and putting others like EQT and CVC on the backfoot. 3i is structured differently, but jitters about private-market values tend to spread quickly.
Markets head into a quieter week for scheduled data, so focus swings to confidence. 3i’s calendar puts its next Q1 update on July 23. Until then, investors are left watching the buyback, signals from Action, and sentiment for listed private equity.
3i’s risk is clear. If Action doesn’t get like-for-like sales back on track in France and Germany, or if margins get hit by inflation or slower foot traffic, the discount to NAV could get bigger instead of smaller. A buyback can help the share count, but it won’t solve slow growth at the most important asset.
Right now, the stock trades on patience. A calmer week could support that. But it won’t settle the Action question.
